Locate Bio obtains multiple late stage orthobiologics assets from RCSI

By Nikita Chaurasia  Date: 2020-09-23

Locate Bio obtains multiple late stage orthobiologics assets from RCSI

Regenerative medicine major, Locate Bio, has reportedly announced its in-licensing of several late stage orthobiologics assets from the RCSI University of Medicine and Health Sciences.

Sources state that the technologies created by the RCSI Tissue Engineering Research Group have wide human and pre-clinical data which efficaciously demonstrates their effectiveness in the treatment of both, soft and hard, tissues. The RCSI licensing transaction comprises natural collagen-based, best in class, and proprietary delivery technologies, that have been developed into numerous products for the regeneration of cartilage tissues, regeneration of bone, and the treatment of infections.

According to John von Benecke, the CEO of Locate Bio, the company is thrilled by the addition of these late stage, high-quality, and complementary products to its portfolio. He has further stated that this is a significant step in the company’s drive towards the development of a world leading orthobiologics enterprise, with its key platforms now covering numerous key areas across the clinical use waterfront.

Locate Bio continues to make excellent advancement toward spinal fusion with its lead product and eagerly looks ahead towards bringing these new assets via the process of regulatory approval in the forthcoming years, added Benecke.

Reliable sources state that Locate’s in-licencing of the assets from RCSI delivers additional breadth and depth to its existing orthobiologics portfolio, further accelerating its route to market. The company is reportedly in search of additional in-licencing or complementary acquisition opportunities that would widen its portfolio of giving surgeons the choice of best-in-class products and technologies that address the existing challenges of present products, also meeting the specific patient clinical requirement.

Ian Wilding, the Chairman at Locate Bio, has stated that the acquisition of these late stage orthobiologics assets progresses Locate’s aspirations and is another significant step in the company’s strategy towards the development of a complementary and differentiated portfolio of innovative products, with high value, strong IP, and a well-state path to market.

 

Source Credits:

https://www.locatebio.com/locate-bio-acquires-complementary-late-stage-orthobiologics-assets/

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

France might ban short domestic flights to reduce its carbon footprint

France might ban short domestic flights to reduce its carbon footprint

By Nikita Chaurasia

French lawmakers recently came to a unanimous decision to ban domestic flights for distances that can be covered by train in over two-and-a-half- hours. The country aims to impose these restrictions in an effort to reduce carbon emissions, even as th...

Kavak secures USD 485 million in funding, eyes Latin America expansion

Kavak secures USD 485 million in funding, eyes Latin America expansion

By Nikita Chaurasia

Kavak, a Mexico-based used-car platform, has reportedly reached a valuation of USD 4 billion after securing USD 485 million during a new funding round. This makes it the fastest-growing as well as the most valued company in Latin America. The latest...

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical t...

LinkedIn confirms launch of a social audio platform to rival Clubhouse

LinkedIn confirms launch of a social audio platform to rival Clubhouse

By Nikita Chaurasia

LinkedIn, the popular employment-oriented online service, has confirmed that it is testing a social audio experience in its app which could offer users with better connectivity in their networks. Although several social media giants such as Twitter ...

Pfizer begins Phase-1 trials of oral COVID-19 antiviral drug in U.S.

Pfizer begins Phase-1 trials of oral COVID-19 antiviral drug in U.S.

By Nikita Chaurasia

Pfizer Inc., an American multinational pharmaceutical corporation, has recently announced to have started the early phase trials for its oral antiviral drug for Coronavirus. The company revealed that first phase trials of the experimental drug, PF-07...